A Phase I Study of IHL-305 (Irinotecan Liposome Injection) in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Study of IHL-305 (Irinotecan Liposome Injection) in Patients With Advanced Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Yakult Honsha
  • Most Recent Events

    • 07 Apr 2009 Additional lead trial investigator identified as Keedy V as reported by Vanderbilt-Ingram Cancer Center.
    • 07 Apr 2009 New source identified and integrated (Vanderbilt-Ingram Cancer Center 1024711)
    • 09 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top